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Abstract Prescriptions for opioid analgesics to manage moderate-to-severe chronic
non-cancer pain have increased markedly over the last decade. An uninten-
tional consequence of greater prescription opioid utilization has been the par-
allel increase in misuse, abuse and overdose, which are serious risks associated
with all opioid analgesics. In response to disturbing rises in prescription opioid
abuse, the US Food and Drug Administration (FDA) has proposed the im-
plementation of aggressive Risk Evaluation andMitigation Strategies (REMS).
While REMS could dramatically change the development, release, marketing
and prescription of extended-release opioids, questions remain on how these
programmes may influence prescribing practices, patient safety and ultimately
patient access to these agents. The extent of the availability and misuse of pre-
scription opioids in Europe is difficult to assess from the data currently avail-
able, due in large part to the considerable differences in prescribing patterns and
regulations between countries. Balancing the availability of prescription opioids
for those patients who have pain, while discouraging illicit use, is a complex
challenge and requires effective efforts on many levels, particularly in Europe
where policies are quite different between countries.
1. Background
Chronic pain is prevalent in 5–33% and 22% of
US and European populations,[1,2] respectively.
This highly prevalent condition places a substantial
burden on patients in terms of personal suffering,
reduced productivity and healthcare costs. Chronic
pain remains inadequately treated in many patients.
Successful management of chronic pain should be
individually tailored to each patient, taking into
account his or her pain intensity and duration, dis-
ease state, tolerance of adverse events and risk of
medication abuse or diversion. A number of long-
acting (LA) opioids have demonstrated sustained
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improvements in pain intensity and pain-related
sleep disturbances in appropriately selected patients
with moderate-to-severe chronic pain, particularly
when used as part of a comprehensive pain man-
agement plan.[3] Prescriptions for extended-release
(ER) opioid analgesics for moderate-to-severe
chronic non-cancer pain have increased markedly
over the last decade,[4] as have postmarketing re-
ports of adverse events associated with opioids.
Two percent of the US population use opioids
regularly,[5] with a 19% increase in the number of
patients from 2000 to 2005. The increased use of
prescription opioids over the last decade has been
mirrored in an increase in the reported misuse,
abuse and diversion of these agents, as well as
overdose and death.[6,7] Clinicians can implement
procedures such as careful patient screening and
on-goingmonitoring tominimize the risk of opioid
abuse without interfering with appropriate use in
patients with legitimate chronic non-cancer pain.
There is significant concern regarding the mis-
use and abuse of opioid prescriptions, and that
this problem has a huge impact on public health.[8]
This article briefly reviews health issues related to
opioid prescription, describes the Risk Evaluation
and Mitigation Strategies (REMS) for ER opi-
oids, the possible limitations and the existing sit-
uation in Europe.
2. Health Issues Related to Opioid Use for
Chronic Non-Cancer Pain
Moderate-to-severe pain is the US FDA-
approved indication for nearly all opioids when
pain relief is needed for a long stretch of time. Such
overly broad indications imply that the FDA has
established that long-term use of opioids is safe
and effective. Many clinicians may be under the
false impression that chronic opioid therapy is an
evidence-based treatment for chronic pain and
that dose-related toxicities can be avoided by slow
upward titration. These misinterpretations lead to
over-prescribing and high-dose prescribing.[9] An
increased body of medical literature suggests that
long-term use of opioids is problematic, especially
when prescribed in high doses.[10]
It has been shown that the rate of addiction in
patients receiving opioids for chronic pain condi-
tions is high, and estimates of the prevalence of
abuse range from 12% to 43%, four times higher
than rates for the general population.[11,12] More-
over, the most dramatic increase in drug overdose
deaths has been observed with the prescription of
opioid medications. The risk of overdose is in-
creased in patients prescribed higher doses of oral
morphine equivalents.[13]
In an attempt to prevent abuse, pharmaceutical
companies are engineering medications with sev-
eral fundamentally different technologies, each
with its own strengths and weaknesses. Tamper
resistance impedes efforts to break an ER pill down
and extract its active ingredients in a fast-acting
form. Some formulae guard only against crushing.
Others resist many manipulations. Chemical com-
binations mix standard analgesics with antidotes
that block the ‘high’ or with irritants that annoy
users. Some formulations only release the second
drug if the pill is crushed or otherwise manipulated.
Others are engineered to resist over-ingestion. Pro-
drugs replace standard analgesics with chemicals
that only activate when processed in the digestive
system, which means they do nothing if smoked,
snorted, injected or otherwise routed around the
digestive system. Finally, novel delivery systems do
away with pills. Patches worn on the skin have
medication woven into the material so that it is very
hard to extract. Implantable analgesic delivery sys-
tems canhave a 1-month supply packed into a device
inserted under the skin. Before approving any new
formulation designed to resist manipulation or curb
abuse, the FDA has to see that it works as ad-
vertised, and themanufacturermust earn the right to
market the drugs as ‘safer’ by meeting targets set as
part of multi-year REMS assigned to each drug
at approval. Without labels that proclaim greater
safety, there can be little justification to force patients
or insurers to pay extra for the new formulations,
and yet the only way to test the downstream benefits
of the new medications will be to pay extra.[14]
These issues stress the clinical value of utilizing
risk assessment prior to initiating opioid therapy,
appropriate prescribing practices, and counselling
patients. Patients may be overwhelmed by infor-
mation about drugs with REMS requirements,
which could discourage the use of potentially
beneficial therapies.[15]
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In response to disturbing rises in prescription
opioid abuse, the FDA has proposed the im-
plementation of aggressiveREMSwhen a question
exists as to whether the benefits of a drug outweigh
its risks.[16] TheUSFDAAmendments Act of 2007
was signed into law on 27 September 2007. This act
authorizes the FDA to require pharmaceutical
manufacturers and distributors to ensure that the
safety of their products continues to outweigh the
risks. The new powers ascribed to the FDA are
notable, as they add enforceability to safety strat-
egies that were not part of the FDA’s prior risk
management tools: risk minimization action plans.
Failure to comply withREMS can lead to financial
penalties of up to $US10million, and a drug could
be deemed misbranded if the REMS is not fol-
lowed. The new approach to risk management via
the FDA has elevated the rigor with which manu-
facturers must fulfil postmarketing safety commit-
ments.[17] The FDA has recently been petitioned to
tighten label restrictions for opioid analgesics as a
way to combat the epidemic of addiction and fatal
overdoses associated with these drugs.[9]
3. Possible Benefits
A REMS may ensure that the benefits of an
opioid medication outweigh the risks. The FDA
indicated a need for a class-wide REMS for ER
opioids as early as 2009. A REMS for ER opioids
was developed by the FDA in April 2011 as a re-
sult of stakeholder, industry, public and advisory
committee meetings held over several years,[18,19]
although the provider participation in this REMS
is currently voluntary. This project was designed to
mitigate the serious risks of opioid-related adverse
outcomes through provider training and patient
education. Unlike many of the FDA safety warn-
ings and communications that are often ignored,
REMS programmes for LA/ER opioids uniquely
provide education and enrolment prior to dispens-
ing and prescribing. Therefore, an opioid REMS is
more likely to impact how these agents are pre-
scribed and dispensed than any of the previously
released FDA warnings.[20]
Potential components of REMS include med-
ication guides, patient package inserts, commu-
nication plans for healthcare providers and elements
to ensure safe use (e.g. special training or certifica-
tion for prescribing or dispensing, dispensing only
under certain circumstances, special monitoring, use
of patient registries).[6,21]
3.1 Medication Guide
The purpose of a medication guide is patient
education. It provides specific information about
risks and safe use of the particular opioid to be
prescribed and products in the class. This guide
outlines symptoms of overdose and the risks asso-
ciated with manipulating the product (e.g. break-
ing or crushing the tablet) or sharing medications
with others. Patients are advised to store medica-
tions in a safe place and to dispose of unused or
expired medications. Patients are also warned of
the risks associated with combining them with
other substances that act on the central nervous
system, or with alcohol or illegal drugs.
3.2 Communication Plan
The purpose of a communication plan is provider
education. It underlines the importance of REMS,
informs about product-specific risks, and provides
protocols for safe use and patient monitoring.
3.3 Elements to Assure Safe Use
The purpose of REMS is the safe access to
otherwise unavailable medications. Education pro-
grammes should include general information for
safe opioid prescribing, product-specific informa-
tion and patient counselling, as well as information
on dispensing, monitoring and follow-up, and en-
rolment in a registry.
3.4 Implementation System
The purpose of an implementation system is to
pre-emptively ensure compliance. It includes certi-
fication prior to prescribing or dispensing, and re-
stricting dispensing and distribution to authorized
people or entities.
3.5 Timetable for Submission of Assessments
The purpose of the assessments is to determine
whether REMS is meeting desired goals through
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periodic effectiveness assessments of the overall
programme and each component.
4. Possible Limitations
The FDA has publically stated that a REMS
for LA/ER opioids was necessary due to the po-
tentially increased risks from dosage forms with
possibly lethal amounts of opioids (e.g. oxycon-
tin 80mg), which could pose increased risks versus
immediate-release (IR) products, which typically
contain less drug per dosage form (tablet, capsule,
etc.). This approach has been criticized because it
implies that the IR forms are ‘safer’ than the
ER/LA opioids.[8]
It seems to be necessary to include all opioids in
a REMS because if REMS exist only for ER/LA
opioids, then prescribers will naturally stop pre-
scribing them and shift to IR opioids, which do not
have a REMS requirement. Interestingly, although
the Centers for Disease Control and Prevention
(CDC) have recently released a report on increased
deaths from methadone, no data indicate that
ER/LA are more dangerous than IR opioids.[22]
Critics of the FDA’s REMS for ER/LA opioids
are chiefly concerned with its voluntary prescriber
education, as well as the fact that that education will
be underwritten by the drug makers.[21] More than
20 opioidmanufacturers will be available to provide
continuing education programmes to prescribers on
the proper use of these drugs. It should be clear that
these programmes, sponsored by drug manufac-
turers, are not based on evidence, and in some cases
fail to provide appropriate information. A coalition
of experts complained of the overly broad indi-
cations for all IR opioids as well as ER opioid for-
mulations and the lack of mention of the risk of
addiction to or dependence on the drugs,[9] and that
aggressive marketing by drug companies may be
responsible for over-prescribing. Indeed, an increas-
ing body of evidence suggests that long-term use of
opioids, especially when prescribed in high doses,
may be neither safe nor effective for many patients.
Thus, they propose (i) striking the term ‘moderate’
from the indication for non-cancer pain; (ii) that the
maximumdaily dose be equivalent to 100mg of oral
morphine; and (iii) that the maximum duration for
continuous daily use be 90 days. In their opinion,
the label changes would not prevent physicians
fromprescribing opioids at doses and durations that
they deem appropriate on a case-by-case basis.
It is expected that once the programme is fully
implemented, the number of clinicians prescribing
ER/LAopioids is likely to decline. Physicians could
stop prescribing ER opioids because of the per-
ception that their prescribing practices will be more
closely monitored.[20] A substantial proportion of
primary care physicians would not be willing to
prescribe opioids controlled by the new REMS,
which could have the unintended effect of decreas-
ing access to these medications for legitimate med-
ical purposes.[23] Patients may be overwhelmed by
information about drugs with REMS require-
ments, which could deter the use of potentially ben-
eficial therapies.[15] Thus, these issues could not
address the needs of a multitude of patients who
have been appropriately prescribed opioid medica-
tions. Other voices suggest that the availability of
these drugs should be ensured for patients who can
benefit from them and concrete approaches to lim-
iting abuses and misuses should be established.[9]
While it is obvious that more education on
chronic pain and the use of opioids is mandatory,
and information should not be influenced by indus-
try, it is also clear that physicians should be given
responsibility for prescribing opioids in proper in-
dications, prescription and monitoring. Demonizing
the drug could mean ignoring the responsibility of
the prescriber.
Other possible sources of drugs are not included
in the education process. The majority of people
who are currently abusing opioid analgesics receive
them from a friend or neighbour.[24] Any attempt
to address the rising problem of drug-related over-
dose deaths that focusses only on educating patients,
providers and pharmacists may have a limited im-
pact, as friends, parents, children and others with
whom the patient comes in contact are not involved
in this programme.[20] It is likely that REMS will
not be influent for patients able to find an approved
prescriber and enrolled pharmacy. However, given
the existing disparity, patients who have insufficient
healthcare resources may find these medications
no longer available to them. This programme
could change how chronic therapy is delivered.
While the REMS programmemay have theoretical
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capabilities for evaluating and addressing proble-
matic drug use among prescribed patients, it is
unlikely to reduce the bulk of prescription drug
abuse that occurs with non-patients.[25]
Finally, any effective opioid REMS programme
should include all opioids, including IR opioids,
particularly in combination with other drugs, and
highlight the risks associated with combining them
with other substances acting on the central nervous
system (e.g. benzodiazepines, anticonvulsants, anti-
depressants and alcohol).[20]
5. European Perspective
The extent of the availability and misuse of pre-
scription opioids in Europe is difficult to ascertain
from the data currently available. Moreover, direct
comparisons between the EU and other parts of the
world are difficult, due in large part to the con-
siderable differences that exist in prescribing pat-
terns and regulations. There are huge discrepancies
in the access to and consumption of opioids between
EU countries, with northern countries having the
largest opioid consumption.[26] Formulary defi-
ciencies and excessive regulatory barriers interfere
with appropriate patient care in many European
countries, raising an ethical and public health im-
perative to address these issues.[27] Whether or not
general practitioners prescribe opioids for persistent
non-cancer pain is mainly determined by their per-
sonal beliefs about appropriateness of opioids for
this indication.[28]
The European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA) was established
in 1993. Inaugurated in Lisbon in 1995, it is one of
the EU’s decentralized agencies. The EMCDDA
exists to provide the EU and its member states with
a factual overview of European drug problems and
a solid evidence base to support the drugs debate.
Today it offers policy makers the data they need
for drawing up informed drug laws and strategies.
It also helps professionals and practitioners work-
ing in the field pinpoint best practice and new areas
of research. However, most data concern injection
drugs and illicit use or clients of maintenance
programmes. Despite a dramatic increase in treat-
ment availability over the years, the number of users
dying of drug overdose in Europe has remained the
same. Reducing overdose fatalities therefore re-
presents a major challenge for drug services across
Europe.[29]
6. Expert Opinion
REMS could dramatically change the develop-
ment, release, marketing and prescription of
LA/ER opioids. However, the direction of these
changes is unpredictable. Questions remain on how
these programmes may influence prescribing prac-
tices, patient safety and, ultimately, patient access
to these agents. The impact of any opioid REMS
programme should be determined with an appro-
priate audit. While it is important to provide the
best care for patients, the primary obligation of all
healthcare providers is to appropriately address
and manage pain. The challenge of balancing the
availability of prescription opioids to treat patients
who have pain while discouraging illicit use is
complex and requires effective efforts on many
levels. REMS requirements are challenging, but the
FDA is cognizant of the need to balance the goals
of ensuring drug safety and providing patient ac-
cess to drugs without placing an undue burden on
the health system.[23] Similar processes should be
performed in Europe, where the different health-
care systems restrict the ability to gather systematic
data and to create homogeneous solutions.
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